Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | HPGD | P15428 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | NMT1 | P30419 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | CLK1 | P49759 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | NMT2 | O60551 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31603107 | 1.00 | MAPT (0.63) | MAPTALDH1A1HPGDLMNASMN1; SMN2 | |
| Butane SCHEMBL3825261 | 0.97 | MAPT (0.61) | MAPTALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL30855071 | 0.95 | MAPT (0.61) | MAPTALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL29896399 | 0.93 | MAPT (0.55) | MAPTALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL18285426 | 0.93 | MAPT (0.55) | MAPTALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL618410 | 0.91 | MAPT (0.62) | MAPTALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL1040706 | 0.90 | MAPT (0.54) | MAPTALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL620990 | 0.88 | MAPT (0.53) | MAPTALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL620385 | 0.88 | NMT1 (0.53) | MAPTALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL6197990 | 0.86 | TP53 (0.63) | MAPTALDH1A1HPGDLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275954-A1 | USE OF KYNURENIC ACID RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARATION OF XOD INHIBITOR | UNIV JIMEI (CN) | 2025-09-04 | — | — | US | claimed |
| WO-2025107568-A1 | USE OF KYNURENIC ACID IN RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARING XOD INHIBITOR | 集美大学 | 2025-05-30 | — | — | WO | claimed |
| CN-117883445-A | Application of hyperuricemia resistance of canine uric acid and structural analogue thereof in preparation of XOD inhibitor | 集美大学 | 2024-04-16 | — | — | CN | claimed |
| EP-4155300-B1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | US HEALTH (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250275954-A1 | USE OF KYNURENIC ACID RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARATION OF XOD INHIBITOR | UNIV JIMEI (CN) | 2025-09-04 | — | — | US | disclosed |
| EP-2603098-B1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | FIRMENICH INCORPORATED (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025107568-A1 | USE OF KYNURENIC ACID IN RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARING XOD INHIBITOR | 集美大学 | 2025-05-30 | — | — | WO | disclosed |
| WO-2025111318-A1 | SOMATOSTATIN SUBTYPE RECEPTOR 3 (SSTR3) AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2025-05-30 | — | — | WO | disclosed |
| CN-117883445-A | Application of hyperuricemia resistance of canine uric acid and structural analogue thereof in preparation of XOD inhibitor | 集美大学 | 2024-04-16 | — | — | CN | disclosed |
| EP-3704102-B1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | US HEALTH (US) | 2024-02-28 | — | — | EP | disclosed |
| US-11795177-B2 | Substituted quinoline analogs as aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-24 | — | — | US | disclosed |
| WO-2003018021-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | AMGEN INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| EP-1266888-A1 | QUINOLINE DERIVATIVES AND MEDICINAL USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2002-12-18 | — | — | EP | disclosed |
| EP-1042295-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-10-11 | — | — | EP | disclosed |
| US-6093732-A | PREVENT HERPESVIRAL INFECTIONS, PARTICULARLY, HUMAN CYTOMEGALOVIRAL INFECTION | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-25 | — | — | US | disclosed |
| WO-1999032450-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0045375-B1 | PROCESS FOR THE PREPARATION OF QUINOLINES, NAPHTHYRIDINES AND OTHER NITROGEN-BI-HETEROCYCLIC COMPOUNDS | HÜLS TROISDORF AKTIENGESELLSCHAFT (DE) | 1985-01-23 | — | — | EP | disclosed |
| US-4450166-A | N-(4,5-Dihydro-thiazol-2-yl)-3-quinoline-carboxamides having anxiolytic activity | ROUSSEL UCLAF (FR) | 1984-05-22 | — | — | US | disclosed |
| US-4380632-A | HYDROLYSIS OF THE CARBALKOXY DERIVATIVE BY WATER USING AN ACID CATALYST; PRESSURIZATION; DISTILLATION; NEUTRALIZATION; DECARBOXYLATION | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) | 1983-04-19 | — | — | US | disclosed |
| US-4343804-A | 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds | A. H. ROBINS COMPANY, INC. (US) | 1982-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275954-A1 | USE OF KYNURENIC ACID RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARATION OF XOD INHIBITOR | XDH, DAO, KMO | MAPT 4081/4885ALDH1A1 635/4885HPGD 93/4885 |
| US-11795177-B2 | Substituted quinoline analogs as aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors | ALDH1A1, ALDH1A2, ALDH1B1 | MAPT 3750/4885ALDH1A1 1/4885HPGD 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.